The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of visualized experiments H. 117
Hauptverfasser: Bonetto, Andrea, Rupert, Joseph E., Barreto, Rafael, Zimmers, Teresa A.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States MyJove Corporation 30.11.2016
Schlagworte:
ISSN:1940-087X, 1940-087X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality . Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma . Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength . Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6) , which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism . Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.
AbstractList Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality1. Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma2-4. Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength3-5. Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6)3, which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism2. Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality1. Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma2-4. Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength3-5. Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6)3, which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism2. Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.
Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality1. Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma2-4. Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength3-5. Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6)3, which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism2. Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.
Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation of lipolysis and proteolysis systems. Cancer patients with cachexia benefit less from anti-neoplastic therapies and show increased mortality . Several animal models have been established in order to investigate the molecular causes responsible for body and muscle wasting as a result of tumor growth. Here, we describe methodologies pertaining to a well-characterized model of cancer cachexia: mice bearing the C26 carcinoma . Although this model is heavily used in cachexia research, different approaches make reproducibility a potential issue. The growth of the C26 tumor causes a marked and progressive loss of body and skeletal muscle mass, accompanied by reduced muscle cross-sectional area and muscle strength . Adipose tissue is also lost. Wasting is coincident with elevated circulating levels of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6) , which is directly, although not entirely, responsible for C26 cachexia. It is well-accepted that a primary mechanism by which the C26 tumor induces muscle tissue depletion is the activation of skeletal muscle proteolytic systems. Thus, expression of muscle-specific ubiquitin ligases, such as atrogin-1/MAFbx and MuRF-1, represent an accepted method for the evaluation of the ongoing muscle catabolism . Here, we present how to execute this model in a reproducible manner and how to excise several tissues and organs (the liver, spleen, and heart), as well as fat and skeletal muscles (the gastrocnemius, tibialis anterior, and quadriceps). We also provide useful protocols that describe how to perform muscle freezing, sectioning, and fiber size quantification.
Author Bonetto, Andrea
Barreto, Rafael
Zimmers, Teresa A.
Rupert, Joseph E.
AuthorAffiliation 1 Department of Surgery, Simon Cancer Center and IUPUI Center for Cachexia Research, Innovation and Therapy, Indiana University School of Medicine
AuthorAffiliation_xml – name: 1 Department of Surgery, Simon Cancer Center and IUPUI Center for Cachexia Research, Innovation and Therapy, Indiana University School of Medicine
Author_xml – sequence: 1
  givenname: Andrea
  surname: Bonetto
  fullname: Bonetto, Andrea
– sequence: 2
  givenname: Joseph E.
  surname: Rupert
  fullname: Rupert, Joseph E.
– sequence: 3
  givenname: Rafael
  surname: Barreto
  fullname: Barreto, Rafael
– sequence: 4
  givenname: Teresa A.
  surname: Zimmers
  fullname: Zimmers, Teresa A.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27929469$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtr3TAQhUVJaZ5_IWgTKBS3etmyNoFw6QtSuuhN6U6MdUe5CraUSHZp_n2VJg1pNl3NwHxzOGdmn-zEFJGQI87eSm34u1b1Rr4ge9wo1rBe_9h50u-S_VKuGOsEa_tXZFdoI4zqzB75vt4iXaUxxUZ0dAXZhZgmoOtlSrkZEHKIl_RLWgpSKBRqu8GR-pTpXDe_zcvmliZfN6PDXIvb4q8Ah-Slh7Hg0UM9IBcf3q9Xn5rzrx8_r87OG6d6PjeD0kxIMQyGOSF4z7xTCjXzrZda6wE2bgDBHTDlkCsJbaeM79Br4E6yQR6Q03vd62WYcOMwzhlGe53DBPnWJgj230kMW3uZftpWiE5KUQVePwjkdLNgme0UisNxhIg1tBWilaJaFOa_KO-V7nupparo8VNbj37-3r0CJ_eAy6mUjP4R4cze_dP--Wfl3jzjXJhhDukuTRif0b8BVUOemw
CitedBy_id crossref_primary_10_3390_cancers16132364
crossref_primary_10_1186_s13765_019_0417_5
crossref_primary_10_1002_jcsm_13329
crossref_primary_10_3390_cancers12123787
crossref_primary_10_3390_cancers12082312
crossref_primary_10_1242_dmm_043166
crossref_primary_10_1152_ajpregu_00035_2025
crossref_primary_10_1155_2018_6419805
crossref_primary_10_1242_dmm_032383
crossref_primary_10_1371_journal_pone_0283806
crossref_primary_10_1152_japplphysiol_00173_2024
crossref_primary_10_3389_fmolb_2021_812681
crossref_primary_10_1002_jcsm_12627
crossref_primary_10_1038_s41467_024_48971_1
crossref_primary_10_3389_fcell_2022_960341
crossref_primary_10_3390_nu14112306
crossref_primary_10_1152_japplphysiol_00196_2023
crossref_primary_10_1016_j_canlet_2021_06_030
crossref_primary_10_3389_fcell_2021_690452
crossref_primary_10_1002_jcsm_12303
crossref_primary_10_1088_1758_5090_ac6c4b
crossref_primary_10_1002_jcsm_12745
crossref_primary_10_1016_j_bone_2019_04_012
crossref_primary_10_1038_s41401_019_0275_z
crossref_primary_10_1152_ajpcell_00327_2024
crossref_primary_10_1007_s11010_020_03882_9
crossref_primary_10_1038_s41598_018_30569_5
crossref_primary_10_3389_fphar_2024_1455805
crossref_primary_10_1113_JP283569
crossref_primary_10_1152_ajpregu_00028_2019
crossref_primary_10_1152_ajpcell_00374_2025
crossref_primary_10_3390_cancers12113221
crossref_primary_10_1038_s41598_020_60396_6
crossref_primary_10_3390_nu15010102
crossref_primary_10_1152_ajpcell_00317_2024
crossref_primary_10_3389_fcell_2020_00033
crossref_primary_10_3390_cancers13246389
ContentType Journal Article
Copyright Copyright © 2016, Journal of Visualized Experiments 2016
Copyright_xml – notice: Copyright © 2016, Journal of Visualized Experiments 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
DOI 10.3791/54893
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE - Academic

AGRICOLA
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1940-087X
ExternalDocumentID PMC5226332
27929469
10_3791_54893
Genre Video-Audio Media
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R21 CA190028
– fundername: NCI NIH HHS
  grantid: R01 CA122596
– fundername: NCI NIH HHS
  grantid: R01 CA194593
GroupedDBID ---
223
29L
53G
5GY
AAHBH
AAHTB
AAYXX
ABPEJ
ACGFO
ADBBV
AKRSQ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
DIK
E3Z
GX1
HYE
OK1
RPM
SJN
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c481t-b470232bb90c22180fc44e70f5f3777badcba21ca04ce143a5649f6ef7a1c30b3
IEDL.DBID 223
ISICitedReferencesCount 93
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000415734600014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1940-087X
IngestDate Tue Sep 30 16:58:32 EDT 2025
Fri Jul 11 06:50:30 EDT 2025
Thu Jul 10 19:58:25 EDT 2025
Thu Jan 02 23:10:16 EST 2025
Sat Nov 29 08:14:10 EST 2025
Tue Nov 18 22:17:14 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 117
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c481t-b470232bb90c22180fc44e70f5f3777badcba21ca04ce143a5649f6ef7a1c30b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Correspondence to: Teresa A. Zimmers at zimmerst@iu.edu
OpenAccessLink https://www.jove.com/pdf/54893/the-colon-26-carcinoma-tumor-bearing-mouse-as-model-for-study-cancer
PMID 27929469
PQID 1847883734
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5226332
proquest_miscellaneous_2253223229
proquest_miscellaneous_1847883734
pubmed_primary_27929469
crossref_primary_10_3791_54893
crossref_citationtrail_10_3791_54893
PublicationCentury 2000
PublicationDate 2016-11-30
PublicationDateYYYYMMDD 2016-11-30
PublicationDate_xml – month: 11
  year: 2016
  text: 2016-11-30
  day: 30
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of visualized experiments
PublicationTitleAlternate J Vis Exp
PublicationYear 2016
Publisher MyJove Corporation
Publisher_xml – name: MyJove Corporation
References 22564195 - Int J Exp Pathol. 2012 Jun;93(3):157-71
21519918 - Ann Surg Oncol. 2012 Apr;19(4):1350-6
25539728 - BMC Cancer. 2014 Dec 24;14:997
21163868 - Cancer Res. 2011 Mar 1;71(5):1710-20
15286803 - J Clin Invest. 2004 Aug;114(3):370-8
22476919 - J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):199-211
20615237 - BMC Cancer. 2010 Jul 08;10:363
24489962 - PLoS One. 2014 Jan 29;9(1):e87776
19508174 - Curr Cancer Drug Targets. 2009 Aug;9(5):608-16
16614058 - Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R674-83
10403450 - Lab Anim Sci. 1999 Jun;49(3):319-23
10444430 - Am J Physiol. 1999 Aug;277(2 Pt 1):E332-41
22669242 - Am J Physiol Endocrinol Metab. 2012 Aug 1;303(3):E410-21
23861230 - Muscle Nerve. 2013 Sep;48(3):387-92
21296615 - Lancet Oncol. 2011 May;12(5):489-95
26092726 - J Biol Chem. 2015 Aug 7;290(32):19976-86
21048967 - PLoS One. 2010 Oct 27;5(10):e13604
22296872 - Clin Nutr. 2012 Aug;31(4):499-505
22476918 - J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):111-6
19246111 - Int J Cardiol. 2009 Apr 17;133(3):388-93
16140458 - Cancer Lett. 2006 Jul 28;239(1):78-83
16286249 - Cancer Cell. 2005 Nov;8(5):421-32
19860537 - Expert Opin Emerg Drugs. 2009 Dec;14(4):619-32
18039237 - Dev Med Child Neurol. 2007 Dec;49(12):907-14
26331011 - Bonekey Rep. 2015 Aug 19;4:732
21799891 - PLoS One. 2011;6(7):e22538
18541999 - Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):400-7
7628876 - Int J Cancer. 1995 Jul 28;62(3):332-6
11547537 - Biol Res Nurs. 2001 Jan;2(3):155-66
20036643 - Biochem Biophys Res Commun. 2010 Jan 15;391(3):1548-54
25457061 - Cancer Biol Ther. 2015;16(6):886-97
References_xml – reference: 26331011 - Bonekey Rep. 2015 Aug 19;4:732
– reference: 21799891 - PLoS One. 2011;6(7):e22538
– reference: 21163868 - Cancer Res. 2011 Mar 1;71(5):1710-20
– reference: 18039237 - Dev Med Child Neurol. 2007 Dec;49(12):907-14
– reference: 25539728 - BMC Cancer. 2014 Dec 24;14:997
– reference: 18541999 - Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):400-7
– reference: 16140458 - Cancer Lett. 2006 Jul 28;239(1):78-83
– reference: 19508174 - Curr Cancer Drug Targets. 2009 Aug;9(5):608-16
– reference: 22476919 - J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):199-211
– reference: 22564195 - Int J Exp Pathol. 2012 Jun;93(3):157-71
– reference: 23861230 - Muscle Nerve. 2013 Sep;48(3):387-92
– reference: 21296615 - Lancet Oncol. 2011 May;12(5):489-95
– reference: 20615237 - BMC Cancer. 2010 Jul 08;10:363
– reference: 21048967 - PLoS One. 2010 Oct 27;5(10):e13604
– reference: 25457061 - Cancer Biol Ther. 2015;16(6):886-97
– reference: 19860537 - Expert Opin Emerg Drugs. 2009 Dec;14(4):619-32
– reference: 22476918 - J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):111-6
– reference: 16614058 - Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R674-83
– reference: 24489962 - PLoS One. 2014 Jan 29;9(1):e87776
– reference: 22669242 - Am J Physiol Endocrinol Metab. 2012 Aug 1;303(3):E410-21
– reference: 15286803 - J Clin Invest. 2004 Aug;114(3):370-8
– reference: 10403450 - Lab Anim Sci. 1999 Jun;49(3):319-23
– reference: 20036643 - Biochem Biophys Res Commun. 2010 Jan 15;391(3):1548-54
– reference: 21519918 - Ann Surg Oncol. 2012 Apr;19(4):1350-6
– reference: 10444430 - Am J Physiol. 1999 Aug;277(2 Pt 1):E332-41
– reference: 16286249 - Cancer Cell. 2005 Nov;8(5):421-32
– reference: 22296872 - Clin Nutr. 2012 Aug;31(4):499-505
– reference: 19246111 - Int J Cardiol. 2009 Apr 17;133(3):388-93
– reference: 26092726 - J Biol Chem. 2015 Aug 7;290(32):19976-86
– reference: 7628876 - Int J Cancer. 1995 Jul 28;62(3):332-6
– reference: 11547537 - Biol Res Nurs. 2001 Jan;2(3):155-66
SSID ssj0062058
Score 2.4261746
Snippet Cancer cachexia is the progressive loss of skeletal muscle mass and adipose tissue, negative nitrogen balance, anorexia, fatigue, inflammation, and activation...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
SubjectTerms adipose tissue
animal models
Animals
anorexia
cachexia
Cachexia - etiology
Cancer Research
carcinoma
Cell Line, Tumor
Colonic Neoplasms
Disease Models, Animal
freezing
heart
Humans
inflammation
Interleukin-6
lipolysis
liver
Mice
Muscle, Skeletal
muscles
Muscular Atrophy - etiology
nitrogen balance
patients
proteolysis
Reproducibility of Results
skeletal muscle
spleen
ubiquitin-protein ligase
Title The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
URI https://www.ncbi.nlm.nih.gov/pubmed/27929469
https://www.proquest.com/docview/1847883734
https://www.proquest.com/docview/2253223229
https://pubmed.ncbi.nlm.nih.gov/PMC5226332
WOSCitedRecordID wos000415734600014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVDIW
  databaseName: Journal of Visualized Experiments : JoVE
  customDbUrl:
  eissn: 1940-087X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062058
  issn: 1940-087X
  databaseCode: 223
  dateStart: 0
  isFulltext: true
  titleUrlDefault: https://www.jove.com/journal
  providerName: Journal of Visualized Experiments
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dS8MwED9kqAji98f8jLDXYNJkSfsoQ_FBxQeVvZUkbXCwdTKnuP_eS7tNNxWhtJReaLg77u5Hjt8BNLJAG-VMQr3jjmI-djT23NNYKIUVc2SZKynzb_TdXdxuJ_cLcPrrCb7QCT9vBnoUjLEiZqFlK_qKtCpi5fxNxOGhJ0u3l2F1ZtVsrvlRQM73QX5LLFfr_25pA9bGNSO5qIy8CQt5sQVL1RTJ0TY8oalJC18KGinSCsOBin7PkIe3Xn9ALboypidyixA_J-aVGBLmn3UJVqsEqz8SOglHpO9xJTrAAB9ox4-O2YHHq8uH1jUdj0ugTsZ8SK3UmIAjaxPmIszczDspc8180wuttTWZsyZCwzDpciyTTFPJxKvca8OdYFbsQq3oF_k-EOWk4yLT2jQRnklpFecIwU3CM-NMxurQmCg2dWMu8TDSopsipggqSksV1eFkKvZSkWfMC5xNrJKiW4ezClPkqI8UgSeCc6GF_FsGQxGGI7ySOuxVlpz-JvAiJgj966BnbDwVCLTas1-KznNJrx0qUiGig_82fwgrWD2pigfyCGrDwVt-DIvufdh5HZyUnop33Y4_AfyE4Yk
linkProvider Journal of Visualized Experiments
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Colon-26+Carcinoma+Tumor-bearing+Mouse+as+a+Model+for+the+Study+of+Cancer+Cachexia&rft.jtitle=Journal+of+visualized+experiments&rft.au=Bonetto%2C+Andrea&rft.au=Rupert%2C+Joseph+E.&rft.au=Barreto%2C+Rafael&rft.au=Zimmers%2C+Teresa+A.&rft.date=2016-11-30&rft.pub=MyJove+Corporation&rft.eissn=1940-087X&rft.issue=117&rft_id=info:doi/10.3791%2F54893&rft_id=info%3Apmid%2F27929469&rft.externalDocID=PMC5226332
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1940-087X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1940-087X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1940-087X&client=summon